La Merie Publishing - Research and Markets

Pipeline of FcRn-Targeted Therapies

From

Pipeline of NaPi2b-Targeted Immunotherapies

From

Pipeline of CD73 Inhibitors

From

Pipeline of Interleukin-6 (IL-6) Receptor Antagonists and IL6- Inhibitors

From

Pipeline of Complement C5 Inhibitors & C5 Receptor Antagonists

From

Pipeline of CD47 and SIRP-alpha Targeted Immunotherapy

From

Pipeline of PD-L1 x 4-1BB (CD137) Bispecific Antibodies

From

Pipeline of Claudin 18.2-Targeted Immunotherapy

From

Pipeline of CD40 Agonists and CD40/L Antagonists

From

Vectorized Antibodies By In Vivo Expression Of DNA Or RNA: A Competitive Business, Stakeholder, Technology & Pipeline Analysis From an Industry Perspective

From

PD-1 x VEGF and PD-L1 x VEGF Bispecific Antibodies: A Business, Pipeline And Competitor Analysis From An Industry Perspective

From

2024 Sales of Therapeutic Antibodies, Proteins, Biosimilars, Gene & Cell Therapy and Therapeutic RNA

From

Degrader-Antibody Conjugates 2024: A Landscape Analysis of Stakeholders, Technologies, Pipeline and Partnering from an Industry Perspective

From

Claudin 18.2-Targeted Immunotherapy: A Landscape Analysis of Stakeholders, Drug Modalities, Pipeline and Business Opportunities from An Industry Perspective

From

Claudin 6, Cadherin 17, ROR1 and GPRC5D-Targeted Therapies: Target Expression Profile, Safety & Efficacy of Drug Modalities, Pipeline Review, and Competitive Landscape Analysis

From

ROR1-Targeted Therapy: Target Expression Profile, Safety & Efficacy of Drug Modalities, Pipeline Review, and Competitive Landscape Analysis

From

Cadherin 17: A Target Opportunity To Develop Effector-Enhanced Drug Modalities

From

Claudin 6: A Target Opportunity To Develop Effector-Enhanced Drug Modalities

From

Targeted Protein Degradation by Proteasomal, Lysosomal & Autophagy Pathways 2022: An Industry Landscape Analysis of Stakeholders, Technologies, Pipeline, Partnering and Financing

From

RNA-Targeted Novel Drug Modalities Based on RNA Editing, Epitranscriptomics, Direct RNA Targeting, Splicing Modulation, Translation Regulation, lncRNA & regRNA Targeting & More: a Landscape Analysis of Technologies, Targets, Business and Financing from An Industry Perspective

From